New gout drug dotinurad shows promise in early trial

NCT ID NCT06056570

Completed Disease control Sponsor: Urica Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study tested a new drug called dotinurad in 20 U.S. adults with gout and high uric acid. Researchers looked at how the drug works in the body, both alone and when taken with the standard gout medicine allopurinol. The goal was to understand dosing and potential drug interactions, not to prove long-term benefits.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dotinurad
What this could lead to: If successful, dotinurad could offer a new option to lower uric acid in people with gout, possibly working well with allopurinol.
What could go wrong: This is a small, early-phase study (20 people) focused on drug levels and interactions, not on long-term safety or effectiveness. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GOUT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gout Hyperuricemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GOUT HYPERURICEMIA

Contacts and locations

Locations

Clinical Research of West Florida

Clearwater, Florida, 33765, United States
Endeavor Clinical Trials

San Antonio, Texas, 78240, United States
Panax Clinical Research

Miami Lakes, Florida, 33014, United States
Southwest Rheumatology Research

Mesquite, Texas, 75150, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.